Sarıçam, E.Öcal, A.Iscanlı, M.D.Bozkurt, E.Ilkay, E.Cantekin, ÖF.2024-10-062024-10-0620241875-621210.2174/01157016112591272312080512492-s2.0-85208771792https://doi.org/10.2174/0115701611259127231208051249BACKGROUND: Postoperative atrial fibrillation (POAF) is associated with poor outcomes, including hemodynamic instability, stroke, myocardial infarction, and death. In hemodynamic stable patients, the rhythm-control strategy is more advantageous than rate control. Current standard intravenous amiodarone administration has limited success and a delayed effect; the acute success rate is 44% (8-12 h to several days). PURPOSE: The aim of this study was to evaluate the effectiveness of higher amiodarone loading dosage to restore sinus rhythm in patients with POAF after noncardiac surgery. METHODS: This is a prospective, randomized, controlled single-center study. The study included 39 patients with POAF, divided into group I (n=27) (intravenous 600 mg amiodarone loading dosage over 2 h and infusion of 50 mg/h over a 24-h period) and group II (n=12) (standard protocol; 300 mg of bolus intravenously in 30 min and infusion of 50 mg/h over a 24-h period). The primary endpoint of the study was a restoration of sinus rhythm at the 24th hour. RESULTS: Baseline clinical, laboratory and echocardiographic characteristics of both groups were similar. The patients with higher loading amiodarone dosage had earlier restoration of sinus rhythm (2.38 ± 1.41 vs 8.66 ± 2.87 h, respectively; p=0.015). There was no significant difference in achieving sinus rhythm at the 24th hour between both groups. CONCLUSION: Higher loading amiodarone dosage increased early conversions to sinus rhythm compared with standard amiodarone protocol in patients with POAF. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.eninfo:eu-repo/semantics/closedAccessAmiodaronedosageechocardiographic.laboratorypostoperative atrial fibrillationsinus rhythmComparison of Amiodarone Loading Dosage in the Treatment of Postoperative Atrial Fibrillation: High Versus Standard Dose TreatmentArticleQ2Q1226386390WOS:001308379300001392191150